Moller Financial Services Trims Stock Position in Johnson & Johnson (NYSE:JNJ)

Moller Financial Services cut its holdings in Johnson & Johnson (NYSE:JNJ) by 17.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,371 shares of the company’s stock after selling 1,165 shares during the quarter. Moller Financial Services’ holdings in Johnson & Johnson were worth $800,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of JNJ. Winslow Evans & Crocker Inc. increased its holdings in shares of Johnson & Johnson by 0.3% in the second quarter. Winslow Evans & Crocker Inc. now owns 21,603 shares of the company’s stock worth $3,037,000 after purchasing an additional 69 shares during the last quarter. Lathrop Investment Management Corp increased its holdings in shares of Johnson & Johnson by 1.4% in the second quarter. Lathrop Investment Management Corp now owns 4,901 shares of the company’s stock worth $689,000 after purchasing an additional 69 shares during the last quarter. Reik & CO. LLC increased its holdings in shares of Johnson & Johnson by 0.4% in the second quarter. Reik & CO. LLC now owns 17,727 shares of the company’s stock worth $2,493,000 after purchasing an additional 70 shares during the last quarter. Old North State Trust LLC increased its holdings in shares of Johnson & Johnson by 0.5% in the second quarter. Old North State Trust LLC now owns 13,666 shares of the company’s stock worth $1,922,000 after purchasing an additional 71 shares during the last quarter. Finally, Delta Investment Management LLC increased its holdings in shares of Johnson & Johnson by 1.0% in the second quarter. Delta Investment Management LLC now owns 7,406 shares of the company’s stock worth $1,041,000 after purchasing an additional 71 shares during the last quarter. Institutional investors own 67.44% of the company’s stock.

Shares of NYSE JNJ traded up $0.33 during trading hours on Wednesday, reaching $144.88. The stock had a trading volume of 47,139 shares, compared to its average volume of 8,235,604. The company has a current ratio of 1.25, a quick ratio of 0.99 and a debt-to-equity ratio of 0.40. The firm has a market cap of $380.57 billion, a price-to-earnings ratio of 22.73, a P/E/G ratio of 3.23 and a beta of 0.68. The business’s fifty day moving average price is $148.06 and its two-hundred day moving average price is $146.95. Johnson & Johnson has a 52-week low of $109.16 and a 52-week high of $157.00.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.98 by $0.22. The firm had revenue of $21.08 billion during the quarter, compared to analyst estimates of $20.15 billion. Johnson & Johnson had a return on equity of 35.10% and a net margin of 21.01%. Johnson & Johnson’s quarterly revenue was up 1.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.12 earnings per share. Equities research analysts anticipate that Johnson & Johnson will post 7.99 earnings per share for the current fiscal year.

JNJ has been the topic of several analyst reports. Zacks Investment Research cut Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 price objective on the stock. in a research note on Tuesday, July 7th. Credit Suisse Group boosted their price objective on Johnson & Johnson from $163.00 to $168.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 14th. ValuEngine raised Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Monday, August 3rd. Independent Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $161.00 to $164.00 in a research note on Monday, July 20th. Finally, Stifel Nicolaus lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, August 19th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the company. Johnson & Johnson currently has a consensus rating of “Buy” and an average price target of $164.93.

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,115 shares of the company’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the completion of the sale, the executive vice president now owns 66,658 shares in the company, valued at $10,233,336.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Ashley Mcevoy sold 29,000 shares of the company’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total value of $4,276,630.00. Following the sale, the executive vice president now owns 21,682 shares of the company’s stock, valued at approximately $3,197,444.54. The disclosure for this sale can be found here. 0.27% of the stock is currently owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Story: How does the Beige Book influence monetary policy?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.